FDA WARNING_LETTER - Ribbon SRL - December 15, 2009

On May 27, 2010, the FDA issued a Warning Letter to Ribbon SRL following a December 8-15, 2009 inspection of their pharmaceutical manufacturing facility in Villadose, Italy. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals (21 CFR Parts 210 and 211), rendering their drug products adulterated.

Key violations include: 1. **Inadequate Procedures for Preventing Microbiological Contamination (21 CFR § 211.113(b)):** Process simulations (media fills) for sterile API production did not accurately represent actual operations, lacking routine interventions. The firm's response was inadequate as it did not provide results of repeated simulations, scientific evidence for placebo medium's growth promotion, or documentation of beta-lactamase use to neutralize antibiotics in media. The use of nitrogen gas during simulations was also questioned for potentially inhibiting aerobic organism growth. 2. **Deficient Controls in Clean Areas (21 CFR § 211.42(c)(10)):** There were no dynamic smoke study evaluations to demonstrate that personnel activities during aseptic filling did not compromise sterile API. The firm's response lacked updates on airflow pattern findings and evaluations. 3. **Inadequate Equipment Cleaning and Maintenance (21 CFR § 211.67(a)):** Cleaned multi-